Syntax Bio
PrivateLast Round
Series A
Jun 21, 2026
Total Funding Raised
$29.4M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Syntax Bio is a synthetic biology company that programs the next generation of stem cell-derived therapies and organoids using its proprietary CRISPR-based Cellgorithm platform.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Syntax Bio Comparables
Compare Syntax Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GC Therapeutics | 85% | |
| bit.bio | 80% | |
| Mogrify | 79% |
Syntax Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 21, 2026 | ||||
| Series A | Sep 17, 2024 |
Syntax Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LongGame Ventures | Series A |
| DCVC Bio | Series A |
| Mansueto Office | Series A |
| EGB Capital | Series A |
| Mayo Clinic Ventures | Series A |
| Draper Associates | Series A |
| Astellas Venture Management | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 23, 2026
Grew 21% QoQ, from 14 to 17 employees.
- Jun 21, 2026
$14M round with participation from DCVC Bio and Allegis Capital.
Syntax Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Syntax Bio's valuation, stock price, and market status.
Is Syntax Bio a public or private company?
Syntax Bio is a private company.
What is the current stock price of Syntax Bio?
Syntax Bio is a private company with no public stock price. No recent secondary market data is available.
How much is Syntax Bio worth (valuation)?
Valuation information for Syntax Bio is not publicly available.
Can I buy Syntax Bio stock?
Syntax Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Syntax Bio's last funding round?
Syntax Bio's most recent funding round was Series A on June 21, 2026.
Who are the main investors in Syntax Bio?
Key investors in Syntax Bio include LongGame Ventures, DCVC Bio, Mansueto Office, EGB Capital, Mayo Clinic Ventures.
Will Syntax Bio IPO soon?
No public IPO plans have been announced for Syntax Bio.
How can I track Syntax Bio secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Syntax Bio's secondary market activity and sign up for updates.